Skip to main content
Cipla Ltd. logo

Cipla Ltd. — Investor Relations & Filings

Ticker · CIPLA ISIN · INE059A01026 LEI · 335800KMJJYEDDK82Q34 BSE.NS Manufacturing
Open in API
Filings indexed 2,618 across all filing types
Latest filing 2019-04-05 Regulatory Filings
Country IN India
Listing BSE.NS CIPLA

About Cipla Ltd.

https://www.cipla.com/

Cipla Ltd. is a global pharmaceutical company focused on the development, manufacturing, and marketing of a wide range of generic and branded medicines. The company maintains a diverse portfolio of over 1,500 products across various therapeutic areas, including respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system treatments. It is recognized for its leadership in respiratory care and its historical role in making HIV/AIDS treatment affordable through the introduction of low-cost antiretroviral drugs. Operating with a strong emphasis on research and development, the firm utilizes advanced technology to produce complex generics and drug delivery systems. Its global footprint spans multiple continents, serving healthcare providers and patients in numerous international markets through a robust supply chain and manufacturing infrastructure.

Recent filings

Filing Released Lang Actions
We hereby notify that pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended, the Board of Directors on 4th April, 2019,has, ....
Regulatory Filings Classification · 95% confidence The document is an intimation under SEBI (Prohibition of Insider Trading) Regulations, 2015, notifying the approval of a Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information and a Code of Conduct for Prevention of Insider Trading by the Board of Directors. It includes detailed policies related to insider trading and disclosure practices. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory compliance notification related to insider trading regulations rather than a financial report or announcement of financial results. It is not a report publication announcement since it contains substantive content (the code itself). Therefore, the document fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2019-04-05 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges informing them about the receipt of an Establishment Inspection Report (EIR) from the USFDA following an inspection. It does not contain financial data, detailed reports, or regulatory filings beyond this notification. The length is only 895 characters, indicating it is a brief announcement rather than a full report. There is no indication of financial results, management changes, or other detailed disclosures. This fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-04-04 English
Please find attached letter dated 4th April 2019
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges and a regulatory body, informing them about the receipt of an Establishment Inspection Report (EIR) from the USFDA following an inspection. It does not contain financial data, detailed audit results, or comprehensive report content. The document is essentially an announcement or notification of the inspection outcome, not the full audit or inspection report itself. Given its brevity (895 characters) and nature as an informational notice, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-04-04 English
We wish to inform that the Company''s wholly owned subsidiary in USA i.e. Cipla Technologies LLC, has signed a binding term sheet today with Pulmatrix Inc., ("Pulmatrix") for an investment ....
Capital/Financing Update Classification · 95% confidence The document is a short announcement informing about a binding term sheet signed by Cipla's subsidiary for an investment and co-development opportunity. It does not contain financial statements, detailed financial results, or comprehensive report data. It is an update on a capital investment transaction. The document length is only 1274 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under Capital/Financing Update (CAP).
2019-04-01 English
Updates
Regulatory Filings
2019-04-01 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges and regulatory bodies informing them about the outcome of a US FDA inspection at the company's manufacturing plant. It details the inspection dates, observations received, and the company's commitment to respond. The document is short (1829 characters) and serves as an announcement of regulatory compliance and inspection results rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types. It fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance update.
2019-03-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.